IP Library Granted Patent US 8,703,426
Granted Patent B2
US 8,703,426 · App. 12/032,553 · Granted Apr 22, 2014

Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV

Inventors: Bernhard Laemmle (Bolligen, CH); Helena Elisabeth Schaller-Gerritsen (Muri AG, CH); Miha Furlan (Bern, CH); Peter Turecek (Klosterneuburg, AT); Hans-Peter Schwarz (Vienna, AT); Friedrich Scheiflinger (Vienna, AT); Gerhard Antoine (Gross-Enzersdorf, AT); Randolf Kerschbaumer (Klosterneuburg, AT); Luigina Tagliavacca (Milan, IT); Klaus Zimmermann (Pressbaum, AT)
Assignee: Baxter Innovations GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,426
App. No.
12/032,553
Granted
Apr 22, 2014
Kind
B2
Abstract

The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.

Claims (16)

1. A method for purification of a vWF protease polypeptide comprising the steps of:

(a) contacting a solution comprising vWF protease polypeptide with an antibody that: binds to a polypeptide present in human plasma that exhibits vWF protease activity, has a molecular weight from about 180 kD to about 120 kD as determined by SDS-PAGE under reducing conditions, and comprises the amino acid sequence AAGGILHLELLV (SEQ ID NO: 1);

wherein the polypeptide is contacted with the antibody under physiological conditions whereby the polypeptide binds to the antibody,

(b) eluting the vWF protease polypeptide from the antibody.

2. The method according to claim 1 , wherein the antibody is immobilized on an affinity chromatography gel.

3. The method according to claim 1 , wherein the solution is human plasma.

4. The method according to claim 1 , wherein the antibody binds to the amino acid sequence

(SEQ ID NO:4)

AGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFR

VHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLV

LYITRFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTI.

5. The method according to claim 1 , wherein the antibody is a monoclonal antibody.

6. The method according to claim 1 , further comprising a step of gel filtration or ion exchange chromatography.

7. The method of claim 6 , wherein the ion exchange chromatography step is anion exchange.

8. The method according to claim 1 , further comprising a gel filtration step and an ion exchange chromatography step.

9. The method according to claim 8 , wherein the ion exchange chromatography is anion exchange.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME, EXECUTION DATE, AND ADDRESS OF ASSIGNEE BAXALTA GMBH PREVIOUSLY RECORDED ON REEL 036366 FRAME 0445. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 4, 2016
From: BAXALTA INNOVATIONS GMBH
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 038345/0889 →
CHANGE OF NAME Recorded Mar 29, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXALTA INNOVATIONS GMBH
Reel/Frame 038292/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036366/0445 →
CHANGE OF NAME Recorded Jun 26, 2008
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 021165/0796 →
Continuity (4)
Division 11166288 · Jun 23, 2005
Division 09833328 · Apr 12, 2001
Continuation In Part 09721254 · Nov 22, 2000
Related Publication 20080176312A1 · Jul 24, 2008